Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angela L Chiew1,2,3, Geoffrey K Isbister3,4,5

  • 1Department of Clinical Toxicology, Prince of Wales Hospital, Randwick, New South Wales, Australia.

British Journal of Clinical Pharmacology
|June 26, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11).

British journal of clinical pharmacology·2026
Same author

Poisoning in the elderly is increasing rapidly and is more severe than younger patients.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Understanding Consumer Attitudes and Awareness After Admission to a Toxicology Unit.

Emergency medicine Australasia : EMA·2026
Same author

A Review of 3 Years of Cardiac Arrest Phone Calls to a State-Based Poisons Centre.

Emergency medicine Australasia : EMA·2026
Same author

Use of Point-of-Care Ultrasound During Cardiac Arrest in the Emergency Department: A Multicentre Retrospective Study.

Emergency medicine Australasia : EMA·2026
Same author

Neuromuscular and cytotoxic effects of common cobra (<i>Naja naja</i>) bites in rural Sri Lanka.

Clinical toxicology (Philadelphia, Pa.)·2025
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same journal

Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population-based cohort study.

British journal of clinical pharmacology·2026
Same journal

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.

British journal of clinical pharmacology·2026
Same journal

Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study.

British journal of clinical pharmacology·2026
Same journal

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.

British journal of clinical pharmacology·2026
Same journal

Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy.

British journal of clinical pharmacology·2026
See all related articles

Serotonin toxicity, caused by excess serotonin, is challenging to diagnose. Prompt recognition and aggressive supportive care, not specific antidotes, are crucial for managing severe cases.

Area of Science:

  • Neuroscience
  • Clinical Pharmacology
  • Toxicology

Context:

  • Serotonin syndrome (toxicity) arises from excessive central nervous system serotonin.
  • It stems from medication initiation, overdose, or drug interactions.
  • Diagnosis is challenging due to a lack of definitive criteria.

Purpose:

  • This review examines the pathophysiology, incidence, clinical assessment, and management of serotonin toxicity.
  • It emphasizes the importance of early recognition and management of severe cases.
  • The review highlights the diagnostic challenges and current treatment strategies.

Summary:

  • Clinical assessment is primary for diagnosis, as specific lab tests are absent.
  • The Hunter Serotonin Toxicity criteria are used but validated only for overdose.
Keywords:
cyproheptadineserotonin antagonistserotonin syndromeserotonin toxicitytreatment

Related Experiment Videos

  • Management prioritizes supportive care, agent discontinuation, and symptomatic treatment.
  • Severe toxicity necessitates aggressive measures like benzodiazepines, intubation, paralysis, and cooling.
  • While 5-HT2A antagonists show promise in animal studies, clinical efficacy is uncertain.
  • Antagonists like cyproheptadine lack conclusive evidence; others have limited data.

    • Impact:

    • Effective early resuscitative and supportive care is the cornerstone for severe serotonin toxicity.
    • This review underscores the need for improved diagnostic tools and evidence-based treatment guidelines.
    • Understanding the nuances of serotonin toxicity management can improve patient outcomes and reduce morbidity.